Disc Medicine

IRON

Market cap $2.29B

LOS ANGELES--(BUSINESS WIRE)---- $IRON--IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm.

Investigation examines gap between reported figures and GAAP results at Disc Medicine ahead of its 21.9% stock collapse NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating whether Disc Medicine, Inc. (NASDAQ: IRON) and certain of its officers fulfilled their disclosure obligations to investors in the period leading up to the company's announcement of a Complete Response Letter from the FDA. Shareholders who purchased IRON shares and incurred losses may obtain further information by contacting Levi & Korsinsky.

New York, New York--(Newsfile Corp. - March 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity.

Jean Franchi sold 11,156 shares of common stock in open-market transactions for a total value of ~$720,000, with an average price around $64.51 per share on Feb. 17 and Feb. 18, 2026. The sale represented 13.52% of Franchi's direct holdings, reducing direct ownership from 82,499 to 71,343 shares.

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a review of recent program and corporate developments.

Hedge fund BVF added 650,000 shares of Disc Medicine in the fourth quarter. The quarter-end position value rose by $51.62 million as a result.

Great Point Partners acquired 250,000 shares in IRON during the fourth quarter. The quarter-end position value increased by $19.85 million due to the new investment.

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext.